JP2002517449A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002517449A5 JP2002517449A5 JP2000553081A JP2000553081A JP2002517449A5 JP 2002517449 A5 JP2002517449 A5 JP 2002517449A5 JP 2000553081 A JP2000553081 A JP 2000553081A JP 2000553081 A JP2000553081 A JP 2000553081A JP 2002517449 A5 JP2002517449 A5 JP 2002517449A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- sulfamate
- composition according
- group
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 sulfamate compound Chemical class 0.000 description 20
- 102100038021 Steryl-sulfatase Human genes 0.000 description 8
- 108010087999 Steryl-Sulfatase Proteins 0.000 description 7
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical group NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 102000029749 Microtubule Human genes 0.000 description 3
- 108091022875 Microtubule Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000008512 biological response Effects 0.000 description 3
- 230000004190 glucose uptake Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 150000003431 steroids Chemical group 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 230000005747 tumor angiogenesis Effects 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 108010005041 estrone sulfatase Proteins 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9812535.4 | 1998-06-10 | ||
| GBGB9812535.4A GB9812535D0 (en) | 1998-06-10 | 1998-06-10 | Composition |
| GBGB9910167.7A GB9910167D0 (en) | 1999-04-30 | 1999-04-30 | Composition |
| GB9910167.7 | 1999-04-30 | ||
| PCT/GB1999/001835 WO1999064013A1 (en) | 1998-06-10 | 1999-06-10 | Pharmaceutical composition with tumor necrosis factor a and 2-methoxyestrone-3-o-sulphamate for inhibition of estrone sulphatase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002517449A JP2002517449A (ja) | 2002-06-18 |
| JP2002517449A5 true JP2002517449A5 (enExample) | 2006-06-01 |
Family
ID=26313837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000553081A Pending JP2002517449A (ja) | 1998-06-10 | 1999-06-10 | エストロンスルファターゼの阻害のための腫瘍壊死因子ａおよび２−メトキシエストロン−３−ｏ−スルファメートを有する薬学的組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6676934B1 (enExample) |
| EP (1) | EP1085876B1 (enExample) |
| JP (1) | JP2002517449A (enExample) |
| AT (1) | ATE401896T1 (enExample) |
| AU (1) | AU765386B2 (enExample) |
| CA (1) | CA2334119C (enExample) |
| DE (1) | DE69939171D1 (enExample) |
| ES (1) | ES2310943T3 (enExample) |
| WO (1) | WO1999064013A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040127473A1 (en) * | 1996-12-05 | 2004-07-01 | Reed Michael John | Compound |
| US7078395B1 (en) | 1999-06-16 | 2006-07-18 | Sterix Limited | Methods for treating or preventing cancer by preventing, inhibiting or arresting cell cycling |
| AU783910B2 (en) | 1999-04-30 | 2005-12-22 | Sterix Limited | Use of estrone derivatives as antitumour agents |
| GB9913536D0 (en) * | 1999-06-10 | 1999-08-11 | Sterix Ltd | Use |
| US7335650B2 (en) | 2000-01-14 | 2008-02-26 | Sterix Limited | Composition |
| FR2806303B1 (fr) * | 2000-03-17 | 2002-09-27 | Inst Nat Sante Rech Med | Composes capables de se lier a des proteines constituantes ou associees aux elements du cytosquelette et leurs applications pour la fabrication de medicaments |
| US20020106348A1 (en) * | 2000-07-12 | 2002-08-08 | Peng Huang | Cancer therapeutics involving the administration of 2-methoxyestradiol and an agent that increases intracellular superoxide anion |
| GB0020498D0 (en) * | 2000-08-18 | 2000-10-11 | Sterix Ltd | Compound |
| AU2001279955A1 (en) * | 2000-08-18 | 2002-03-04 | Sterix Limited | 2-substituted estradiol derivative for inhibiting superoxid dismutase |
| GB0113920D0 (en) | 2001-06-07 | 2001-08-01 | Sterix Ltd | Composition |
| US20060051343A1 (en) * | 2002-06-19 | 2006-03-09 | Tatsuya Watanabe | Preventives remedies for bone and joint diseases |
| DE10307103A1 (de) * | 2003-02-19 | 2004-09-09 | Schering Ag | Antitumor wirksame 2-substituierte D-Homostra-1,3,5(10)-trien-3-yl sulfamate |
| DE10307104A1 (de) * | 2003-02-19 | 2004-09-23 | Schering Ag | Antitumor wirksame 2-substituierte Estra-1,3,5(10)-trien-3-yl sulfamate |
| DE10307105A1 (de) * | 2003-02-19 | 2004-09-09 | Schering Ag | Antitumor wirksame 2-substituierte 18a-Homoestra-1,3,5(10)-trien-3-yl sulfamate |
| GB0306717D0 (en) * | 2003-03-24 | 2003-04-30 | Sterix Ltd | Compound |
| AU2004224053B2 (en) * | 2003-03-24 | 2011-06-09 | Sterix Limited | Oestrogen derivatives as inhibitors of steroid sulphatase |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9118478D0 (en) * | 1991-08-29 | 1991-10-16 | Imperial College | Steroid sulphatase inhibitors |
| GB9625334D0 (en) * | 1996-12-05 | 1997-01-22 | Imperial College | Compound |
| US6011024A (en) * | 1991-08-28 | 2000-01-04 | Imperial College Of Science Technology & Medicine | Steroid sulphatase inhibitors |
| JPH0912596A (ja) * | 1995-06-23 | 1997-01-14 | Meiji Milk Prod Co Ltd | 抗癌剤の腫瘍細胞障害作用を増強する新規な蛋白性因子 |
| DE19540233B4 (de) * | 1995-10-19 | 2005-08-25 | Schering Ag | Sulfamat-Derivate von 1,3,5(10)-Estratrien-Derivaten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| CA2266051A1 (en) * | 1996-09-12 | 1998-03-19 | Teikoku Hormone Mfg. Co., Ltd. | 3-substituted-d-homo-1,3,5,(10)-estratriene derivatives |
| US5880115A (en) * | 1997-07-18 | 1999-03-09 | Duquesne University Of The Holy Ghost | Steroid sulfatase inhibitors and methods for making and using the same |
| GB2331988B (en) * | 1997-12-04 | 2003-04-16 | Imperial College | Polycyclic sulphamate inhibitors or oestrone sulphatase |
| US6046186A (en) * | 1997-12-24 | 2000-04-04 | Sri International | Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use |
-
1999
- 1999-06-10 JP JP2000553081A patent/JP2002517449A/ja active Pending
- 1999-06-10 CA CA2334119A patent/CA2334119C/en not_active Expired - Fee Related
- 1999-06-10 WO PCT/GB1999/001835 patent/WO1999064013A1/en not_active Ceased
- 1999-06-10 DE DE69939171T patent/DE69939171D1/de not_active Expired - Lifetime
- 1999-06-10 EP EP99955428A patent/EP1085876B1/en not_active Expired - Lifetime
- 1999-06-10 ES ES99955428T patent/ES2310943T3/es not_active Expired - Lifetime
- 1999-06-10 AU AU42807/99A patent/AU765386B2/en not_active Ceased
- 1999-06-10 AT AT99955428T patent/ATE401896T1/de not_active IP Right Cessation
-
2000
- 2000-11-28 US US09/724,986 patent/US6676934B1/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002517449A5 (enExample) | ||
| Aktas | A comprehensive review on rational and effective treatment strategies against an invisible enemy; SARS Cov-2 infection. | |
| US5767135A (en) | Antiviral agent | |
| US5393772A (en) | Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation | |
| TW303298B (enExample) | ||
| JP2006521335A5 (enExample) | ||
| CA2334119A1 (en) | Pharmaceutical composition with tumor necrosis factor a and 2-methoxyestrone-3-o-sulphamate for inhibition of estrone sulphatase | |
| JP2002543114A5 (enExample) | ||
| Ram et al. | Remdesivir for COVID-19: A review of pharmacology, mechanism of action, in-vitro activity and clinical use based on available case studies. | |
| JP2001524525A5 (enExample) | ||
| JP2002523408A (ja) | ヘリオキサンチンおよびその類似体によるｂ型肝炎ウイルスおよびフラビウイルスの阻害および治療 | |
| EP1089732A1 (en) | Compositions and methods for treating elevated blood cholesterol | |
| JPH11511463A (ja) | インターロイキン変換酵素およびアポプトーシス | |
| US7335679B2 (en) | Wortmannin analogs and methods of using same | |
| JP2003507469A (ja) | 脂肪酸シンターゼ阻害剤 | |
| JP2003521457A5 (enExample) | ||
| CN115487177B (zh) | 一种黄酮类化合物用于治疗溃疡性结肠炎的新用途 | |
| KR101045985B1 (ko) | 아릴 디케토산（ａｄｋ） 유도체를 유효성분으로 포함하는 사스 코로나 바이러스 저해용 조성물 | |
| CN116270564B (zh) | 4,3',5'-三羟基白藜芦醇类化合物在制备冠状病毒3cl蛋白酶抑制剂中的应用 | |
| BR9916733A (pt) | Derivados de arilalcanoìla, processos para sua preparação, seu uso e composições farmacêuticas que os contêm | |
| JPS63156724A (ja) | 逆転写酵素阻害剤 | |
| CN110496128B (zh) | 利培酮或帕潘立酮在制备治疗弥漫性大b细胞淋巴瘤的药物中的应用 | |
| CN121129849A (zh) | 乐伐替尼(Lenvatinib) (E7080)在治疗泡型包虫病中的应用 | |
| JP2003507467A (ja) | 脂肪酸シンターゼ阻害剤 | |
| Lush et al. | Review of three new agents that target angiogenesis, matrix metalloproteinases, and cyclin-dependent kinases |